ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologicals"

  • Abstract Number: 0878 • ACR Convergence 2025

    Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study

    Maria Gabriella Raimondo1, Hashem Mohammadian2, Simon Rauber3, Stefano Alivernini4, Filippo Fagni5, Giulia Corte6, Koray Tascilar7, Alina Mihaela Ramming8, Juergen Rech2, Maria Antonietta D´Agostino9, Georg Schett2, Milena Pachowsky8, Arnd Kleyer10 and Andreas Ramming11, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 3Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, 4Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, 6- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 7Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 94Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 11Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Enthesitis is an early event in the course of psoriatic arthritis (PsA) and a hallmark feature of the disease. Currently, much of the understanding…
  • Abstract Number: 0498 • ACR Convergence 2025

    Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.

    Naveen Reddy1, Narendra Maharaj1, Pramod Kumar Reddy1, Mansi Dhananjaya Jakhade1, Maria Velinova2 and Vendel Kemény3, 1Biologics, Dr. Reddy’s Laboratories Ltd., Hyderabad, India, Hyderabad, India, 2ICON – Early Development Services Van Swietenlaan 6 9728 NZ, Groningen, Netherlands, Groningen, Netherlands, 3ICON Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely Rottenbiller utca 13 1077, Budapest, Hungary, Budapest, Hungary

    Background/Purpose: Dr. Reddy’s-abatacept (DRL_AB) is being developed as a biosimilar to the reference product (RP) (RP-US licensed Orencia®) and the reference medicinal product (RMP) (RMP-EU…
  • Abstract Number: 0238 • ACR Convergence 2025

    Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study

    Alessia Gatti1, Francesca Regola1, Giulia Fontana2, Jacopo Mora2, Mario Andrea Piga3, Gianluca Moroncini3, Rossella Acquaviva4, Palma Carlucci4, Silvia Noviello4, Angelo Vacca4, Paolo Delvino5, Enrico Heffler6, Emanuele Nappi6, Jakub Moll7, Jan Schroeder7, Laura Losappio7, Federica Davanzo8, Roberto Padoan9, Paolo Cameli10, Edoardo Conticini11, Greta Pacini12, Alvise Berti12, Lorenzo Vrola13, Paola Tomietto13, Benedetta Fazzi14, elena treppo15, Luca Quartuccio14, Jan Willem Cohen Tervaert16, Sabrina Arnold17, Prof. Dr. med. Peter Lamprecht18, Florence Roufosse19, Ilaria Cavazzana1, Franco Franceschini20, Giacomo Emmi21 and Paola Toniati22, 1Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, 3Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, 4Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, 5Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, 6Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, 7Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, 8Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, 9Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, 10University of Siena, Siena, Italy, 11Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, 12Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, 13UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, 14Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, 15Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 16University of Alberta, Edmonton, AB, Canada, 17Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, 18University of Lübeck, Lübeck, Germany, 19Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, 20University of Brescia, Brescia, Brescia, Italy, 21Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, 22Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy

    Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
  • Abstract Number: 2467 • ACR Convergence 2025

    Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis

    Richard Furie1, Hans-Joachim Anders2, George Bertsias3, Ana Delgado4, Roger A. Levy5, Paula Curtis6, Ciara O'Shea7, Ryan Tomlinson8 and Brad Rovin9, 1Division of Rheumatology, Northwell Health, Great Neck, NY, 2Hospital of LMU Munich, Department of Medicine IV, Munich, Germany, 3Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, 4GSK, Immunology Medical Affairs, London, United Kingdom, 5GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 6GSK, Biostatistics, London, United Kingdom, 7Global Medical Affairs, GSK, Dublin, Ireland, 8GSK, Development – R&D, Collegeville, PA, 9The Ohio State University, Columbus, OH

    Background/Purpose: Belimumab, a human IgG1λ monoclonal antibody that selectively binds B-lymphocyte stimulator, was first approved in 2011. It is the only biologic approved for LN…
  • Abstract Number: 2346 • ACR Convergence 2025

    Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis

    Daniel Zavada1, Barbora Vala2, Adela Navratilova2, Veronika Losterova2, Lenka Moravcova2, Jiri Vencovsky3, Ladislav Šenolt4, Karel Pavelka5 and Michal Tomcik5, 1Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, 2Institute of Rheumatology, Praha, Czech Republic, 3Institute of Rheumatology, Praha 8, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Ankylosing spondylitis (AS) significantly impacts quality of life across multiple domains. To date, no studies have evaluated the impact of initial biological therapy on…
  • Abstract Number: 2041 • ACR Convergence 2025

    Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review

    Nashwah Memon1, Dylan Wambold2, Omar Alani3, Syed Minhaj Rahman4 and Adel Haque5, 1Lake Erie College of Osteopathic Medicine, Miami, 2Drexel University College of Medicine, Philadelphia, 3Icahn School of Medicine at Mount Sinai, New York, 4Department of Medicine, Northwell Health Northern Westchester Hospital, Mount Kisco, 5Jefferson Health Northeast, Philadelphia

    Background/Purpose: Clinicians prescribing biologics must be aware of the expanding indications for biologic/systemic therapies across dermatology and rheumatology alike. Given disease-state overlap between these fields,…
  • Abstract Number: 1605 • ACR Convergence 2025

    Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

    Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol-Frigole4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins-Martinho10, Camillo Ribi11, Mathieu Groh12 and Benjamin Terrier13, 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 2Sechenov University, Moscow, Russia, 3University of Padova, Padova, Italy, 4Hospital Clínic de Barcelona, Barcelona, Spain, 5University of Alberta, Edmonton, AB, Canada, 6Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, 7CHU Toulouse, Toulouse University, Toulouse, France, 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, 9Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, 10ULS Santa Maria, Lisbon, Portugal, 11Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, 12Hôpital Foch, Suresnes, France, 13Cochin Hospital, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
  • Abstract Number: 1460 • ACR Convergence 2025

    Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study

    Stefan Siebert1, Mohamed Sharaf2, Frank Behrens3, Proton Rahman4, mitsumasa kishimoto5, Enrique R. Soriano6, Emmanouil Rampakakis7, László Köleséri8, Karissa Lozenski9, Ruben Queiro10, Ennio Lubrano11 and Laure Gossec12, 1University of Glasgow, Glasgow, United Kingdom, 2Janssen - Johnson & Johnson, Dubai, United Arab Emirates, 3Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, 4Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, 5Kyorin University School of Medicine, Tokyo, Japan, 6Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7JSS Medical Research, Montréal, QC, Canada, 8IQVIA, Budapest, Hungary, 9Johnson & Johnson, Horsham, PA, 10Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, 11Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, 12Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France

    Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
  • Abstract Number: 1356 • ACR Convergence 2025

    Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study

    Jonathan Kay1, Eugen feist2, Ernest Choy3, Joerg Kaufmann4, Ernest Wong5, Hector Corominas6, René-Marc Flipo7, Jérôme Avouac8, María América López Lasanta9, Joelle Monnet10, Peter Baker11, Maria Romanova Michailidi12, Fabrizio Dolfi11 and Graziella Pourcel13, 1UMass Chan Medical School, Worcester, MA, 2Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 3Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, 4NA, Ludwigsfelde, Germany, 5Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, 6Hospital de Sant Pau, Barcelona, Spain, 7Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, 8Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 9Hospital Universitario Vall d´Hebron, Barcelona, Spain, 10Fresenius Kabi SwissBioSim, Eysins, Switzerland, 11Fresenius Kabi Biopharma, Eysins, Switzerland, 12University of Geneva, Eysins, Switzerland, 13Fresenius Kabi Biopharma, Eyzins, France

    Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
  • Abstract Number: 1122 • ACR Convergence 2025

    A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems

    William Koch1, Donald Anthony2, Janeen Leon2 and Nora G. Singer2, 1University Hospitals Parma Medical Center, Parma, OH, 2The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
  • Abstract Number: 0667 • ACR Convergence 2025

    Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN

    Sawyer May1, Lynn Price1 and Ryan Rex2, 1Spherix Global Insights, Exton, PA, 2Spherix Global Insights, Chester Springs, PA

    Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…
  • Abstract Number: 0875 • ACR Convergence 2025

    Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)

    Lawrence Eichenfield1, Ricardo Galimberti2, Adelaide Hebert3, Wen-Hui Wang4, Jennifer Soung5, Nina Magnolo6, John Browning7, Angela Moore8, Mark Lebwohl9, Dagmar Wilsmann-Theis10, Joseph F Merola11, Georgios Kokolakis12, Dariusch Mortazawi13, Parbeer Grewal14, Megan Miller15, Joseph Cafone16, Shu Li17, Gigi Jiang17, Fabio Nunes17, Cynthia DeKlotz18 and Amy Paller19, 1University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, 2Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, 3University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, 4Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), 5Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, 6University Hospital Muenster, Muenster, Germany, Muenster, Germany, 7Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, 8Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, 9Icahn School of Medicine at Mount Sinai, New York, NY, 10University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, 11Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 12Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 13Clinical Research Center, Remscheid, Germany, Remscheid, Germany, 14University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, 15Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, 16Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, 17Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 18Johnson & Johnson, San Diego, CA, USA, San Diego, CA, 19Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL

    Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
  • Abstract Number: 0493 • ACR Convergence 2025

    Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor

    Maarten Kraan1, Salah Hadi2, Leonie Middelink3, Renato Chirivi3, Eric meldrum3, Naomi Klarenbeek4 and Patrick Round3, 1Citryll BV, Den Dolder, Netherlands, 2ICON Netherlands BV, Groningen, Netherlands, 3Citryll BV, Oss, Netherlands, 4CHDR, Leiden, Netherlands

    Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
  • Abstract Number: 0205 • ACR Convergence 2025

    Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness

    Laura Mas Sanchez1, ELENA GRAU GARCIA2, Carlos Valera Ribera3, Pablo Muñoz-Martínez4, Daniel Ramos Castro5, Alba Maria Torrat Noves6, Belen Villanueva Manes7, Iago Alcántara Álvarez8, Miguel Simeo Vinaixa9, Andres Perez Hurtado10 and José Andrés Román Ivorra11, 1Hospital Universitari i Politecnic La Fe, València, Spain, 2HUP La Fe, Valencia, Comunidad Valenciana, Spain, 3Hospital Universitario Doctor Peset, València, Spain, 4Hospital Universitario y Politécnico La Fe, Sagunto, Spain, 5Hospital Universitari i Politecnic La Fe, Valencia, Spain, 6Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, 7Hospital La Fe, València, Spain, 8Hospital Universitari i Politénic La Fe, València, Spain, 9Rheumatology Department. HUP La Fe, Valencia, Spain, 10Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, 11Hospital Universitari i Politècnic La Fe, Valencia, Spain

    Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
  • Abstract Number: 2689 • ACR Convergence 2025

    Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study

    April Armstrong1, Joseph Merola2, Gang Wang3, Ariane Faucher4, Riley Taiji4, Francis Vekeman4, Alexis Shew5, Tim Nguyen5 and Laura Coates6, 1University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, 2UT Southwestern Medical Center, Dallas, TX, 3Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China (People's Republic), 4STATLOG, Inc, Montreal, QC, Canada, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom

    Background/Purpose: Biologic therapies for moderate to severe psoriasis (PsO) include inhibitors of IL-17 (IL-17i), IL-23i, IL-12/23i, and tumor necrosis factor (TNFi). Previous studies that assessed…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology